NCT01516047View on ClinicalTrials.gov

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Hepatic Impairment
Interventions
DRUG

Cohort 1

125 mg to 2000 mg abiraterone acetate suspension on Day 1

DRUG

Cohort 2

2000 mg abiraterone acetate suspension on Day 1

Trial Locations (3)

Unknown

Anaheim

Orlando

San Antonio

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01516047 - A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function | Biotech Hunter | Biotech Hunter